orphenadrine has been researched along with Parkinson Disease, Secondary in 11 studies
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A trial involving patients receiving fluphenazine decanoate was designed to compare the effects of orphenadrine hydrochloride (Disipal) and its major metabolite, tofenacin hydrochloride (Elamol) on the Parkinsonian side-effects and depression occurring during fluphenazine decanoate therapy." | 9.04 | A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. ( Capstick, N; Pudney, H, 1976) |
| "A trial involving patients receiving fluphenazine decanoate was designed to compare the effects of orphenadrine hydrochloride (Disipal) and its major metabolite, tofenacin hydrochloride (Elamol) on the Parkinsonian side-effects and depression occurring during fluphenazine decanoate therapy." | 5.04 | A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. ( Capstick, N; Pudney, H, 1976) |
| "Ritanserin is a new compound with a high, selective, and long-lasting binding affinity for 5-HT2 receptors." | 2.67 | 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. ( Bersani, G; Ciani, N; Grispini, A; Marini, S; Pasini, A; Valducci, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffman, BF | 1 |
| Mindham, RH | 2 |
| Korczyn, AD | 1 |
| Goldberg, GJ | 1 |
| Capstick, N | 1 |
| Pudney, H | 1 |
| Bersani, G | 1 |
| Grispini, A | 1 |
| Marini, S | 1 |
| Pasini, A | 1 |
| Valducci, M | 1 |
| Ciani, N | 1 |
| Altamura, AC | 1 |
| Mauri, MC | 1 |
| De Novellis, F | 1 |
| Percudani, M | 1 |
| Vampini, V | 1 |
| Vågen, R | 1 |
| Götestam, KG | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Morris, PA | 1 |
| MacKenzie, DH | 1 |
| Masheter, HC | 1 |
| Dogliani, P | 1 |
| Senini, G | 1 |
| Bertuzzi, F | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
7 trials available for orphenadrine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
Extrapyramidal effects of neuroleptics.
Topics: Adult; Age Factors; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Extrap | 1976 |
A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.
Topics: Clinical Trials as Topic; Depression; Fluphenazine; Humans; Orphenadrine; Parkinson Disease, Seconda | 1976 |
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Orphenadrine; Parkinson D | 1990 |
An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Euphoria; Female; Humans; Male; | 1986 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.
Topics: Benzimidazoles; Blood Cell Count; Clinical Trials as Topic; Fluphenazine; Humans; Male; Middle Aged; | 1970 |
4 other studies available for orphenadrine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The diagnosis and treatment of neuroleptic-induced Parkinsonism.
Topics: Antipsychotic Agents; Depression; Diagnosis, Differential; Diphenhydramine; Humans; Neurologic Exami | 1981 |
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
Topics: Adult; Aged; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease, Second | 1989 |
Clinical observations on the therapeutic activity of flupentixol in the treatment of chronic schizophrenia.
Topics: Adult; Aged; Blood; Body Weight; Chlorpromazine; Chronic Disease; Delusions; Depression, Chemical; F | 1970 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |